These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8817161)

  • 1. Rate of development of mutation at codon 215 of HIV-1 reverse transcriptase and its predictive factors at the time of initiation of zidovudine therapy.
    Leal M; Rey C; Torres Y; Relimpio F; Pino R; Lissen E; Sánchez-Quijano A; Luque F
    Eur J Clin Invest; 1996 Jun; 26(6):476-80. PubMed ID: 8817161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
    Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
    AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reverse transcriptase mutations in HIV-1-infected children treated with zidovudine.
    Unal A; Lorenzo E; Brown M; Smith L; Matsuura S; Scott G; Scott W
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Oct; 13(2):140-5. PubMed ID: 8862278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):832-8. PubMed ID: 7517448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients.
    Calderón EJ; Torres Y; Medrano FJ; Luque F; Larder B; Rey C; Sánchez-Quijano A; Lissen E; Leal M
    Eur J Clin Microbiol Infect Dis; 1995 Jun; 14(6):512-9. PubMed ID: 7588824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1.
    Leriche-Guérin K; Trabaud MA; Cotte L; Bissuel F; Deruelle E; Rougier P; Trépo C
    Eur J Clin Microbiol Infect Dis; 1997 Sep; 16(9):660-8. PubMed ID: 9352259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
    Kozal MJ; Kroodsma K; Winters MA; Shafer RW; Efron B; Katzenstein DA; Merigan TC
    Ann Intern Med; 1994 Aug; 121(4):263-8. PubMed ID: 7518658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
    Yerly S; Denereaz N; Mermillod B; Hirschel B; Perrin L
    Antivir Ther; 1996 Aug; 1(3):167-71. PubMed ID: 11322250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term evolution of HIV-1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine.
    Rubio A; Leal M; Rey C; Pineda JA; Sanchez-Quijano A; Lissen E
    AIDS; 1998 Mar; 12(4):395-8. PubMed ID: 9520169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
    Ross L; Johnson M; Graham N; Shaefer M; St Clair M
    J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study.
    Kully C; Yerly S; Erb P; Kind C; Krautheim A; Perrin L; Rudin C
    J Infect Dis; 1999 Mar; 179(3):705-8. PubMed ID: 9952382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine.
    Principi N; Marchisio P; De Pasquale MP; Massironi E; Tornaghi R; Vago T
    AIDS Res Hum Retroviruses; 1994 Jun; 10(6):721-6. PubMed ID: 7521192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.
    Richman DD; Guatelli JC; Grimes J; Tsiatis A; Gingeras T
    J Infect Dis; 1991 Dec; 164(6):1075-81. PubMed ID: 1720152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.
    Rusconi S; De Pasquale MP; Mainini F; Bulgheroni E; Kurtagic S; Gori A; Violin M; Zanchetta N; Moroni M; Balotta C; Galli M
    Antivir Ther; 1996 Dec; 1(4):211-9. PubMed ID: 11324823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
    Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
    J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid detection of the HIV type 1 reverse transcriptase codon T215Y by reverse transcription-polymerase chain reaction with fluorogenic probes.
    Ross L; Vavro C; Zimmermann A; St Clair M
    AIDS Res Hum Retroviruses; 1999 Sep; 15(14):1287-92. PubMed ID: 10505677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.